Vital Images has filed a 510(k) application with the Food andDrug Administration for a new, more advanced version of its 3-Dimage processing software, according to the company's parent,Bio-Vascular of St. Paul, MN. The new version builds on VitalImages'
Vital Images has filed a 510(k) application with the Food and
Drug Administration for a new, more advanced version of its 3-D
image processing software, according to the company's parent,
Bio-Vascular of St. Paul, MN. The new version builds on Vital
Images' existing 3-D product, VoxelView 2.5, but is faster and
easier to use. The company plans to display the new version at
this year's Radiological Society of North America meeting. Vital
Images has an agreement with ATL of Bothell, WA, to develop 3-D
ultrasound image processing software (SCAN 8/28/96).
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.